RA0521

antibody from Oursmab

Targeting: NGF NGFB

Western blot (Supportive data in Antibodypedia)

ELISA (Supportive data in Antibodypedia)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0521

Provider

Oursmab

Product name

Luvagrobart (Biosimilar Reference Antibody) (NGF)

Antibody type

Monoclonal

Description

Luvagrobart is a humanized IgG1-kappa (IgG1¦Ê) monoclonal antibody that specifically targets nerve growth factor (NGF), a key neurotrophin involved in pain signaling. As an IgG1 isotype, it is designed to potentially engage effector functions. By binding to and neutralizing NGF, it blocks the interaction between NGF and its high-affinity receptor TrkA (tropomyosin receptor kinase A) on nociceptive neurons. This inhibition aims to reduce the sensitization and hyperexcitability of pain-sensing neurons, thereby alleviating chronic pain. It is being developed as a non-opioid analgesic for the treatment of moderate-to-severe chronic pain conditions, such as osteoarthritis pain and chronic low back pain.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Luvagrobart (Biosimilar Reference Antibody) (NGF)-RA0521-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.

ELISA

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

ELISA plate pre-coated Antigen protein, can bind Luvagrobart (Biosimilar Reference Antibody) (NGF)-RA0521 in a linear range of 0.18¨C15 ng/mL.